Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy

Autor: Marco Turatti, Fabio Benedetti, Cristina Tecchio, Guido Cavaletti, Marco Sorio, Salvatore Monaco, Sergio Ferrari, Laura Bertolasi, Maria Chiara Tozzi, Sara Mariotto
Přispěvatelé: Mariotto, S, Tecchio, C, Sorio, M, Bertolasi, L, Turatti, M, Tozzi, M, Benedetti, F, Cavaletti, G, Monaco, S, Ferrari, S
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
Cancer Research
peripheral neuropathy
CD30
assessment
adverse event
Pharmacology
chemistry.chemical_compound
0302 clinical medicine
Antineoplastic Agents
Immunological
immune system diseases
hemic and lymphatic diseases
Medicine
Prospective Studies
Brentuximab vedotin
Brentuximab Vedotin
integumentary system
biology
Lymphoma
Non-Hodgkin
Peripheral Nervous System Diseases
Hematology
Middle Aged
Prognosis
Hodgkin Disease
Oncology
Monomethyl auristatin E
030220 oncology & carcinogenesis
Female
Antibody
medicine.drug
Adult
brentuzimab vedotin
neurotoxicity
peripheral nerve
03 medical and health sciences
Young Adult
Humans
Adverse effect
Aged
therapy
business.industry
brentuximab vedotin (BV)
Neurotoxicity
medicine.disease
Peripheral neuropathy
chemistry
Cancer cell
biology.protein
Neoplasm Recurrence
Local
business
030215 immunology
Follow-Up Studies
Popis: Brentuximab vedotin (BV) is an anti-CD30 antibody acting against CD30+ cancer cells through the release of the conjugated microtubule-disrupting agent monomethyl auristatin E (MMAE). BV is currentl...
Databáze: OpenAIRE
Externí odkaz: